Kite Pharma, NCI Team To Develop Autologous T Cell Therapeutics For Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Under a Cooperative Research and Development Agreement, Kite will provide R&D funding and obtain options to license any of NCI’s eACT candidates.